Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results (Clinical Rheumatology, (2022), 10.1007/s10067-022-06218-8)

Laura C. Coates, Philip Mease, Andris Kronbergs, Cameron Helt, David Sandoval, So Young Park, Bernard Combe, Peter Nash, Atul Deodhar

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results (Clinical Rheumatology, (2022), 10.1007/s10067-022-06218-8)'. Together they form a unique fingerprint.

Medicine & Life Sciences